Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized open-label study comparing the efficacy and safety of sirolimus combined with daclizumab, mycophenolate and corticosteroids vs cyclosporine, mycophenolate and corticosteroids in renal allograft recipients receiving kidneys from older donors.

Next Previous
X
Search
Trial Profile

A randomized open-label study comparing the efficacy and safety of sirolimus combined with daclizumab, mycophenolate and corticosteroids vs cyclosporine, mycophenolate and corticosteroids in renal allograft recipients receiving kidneys from older donors.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Daclizumab (Primary) ; Sirolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Sponsors Wyeth

    • Most Recent Events

    • 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
    • 15 Sep 2009 Actual number of patients (61) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top